With a market cap of $1.3 trillion, Eli Lilly and Company (LLY) discovers, develops, manufactures, and markets medicines across major regions including the United States, Europe, China, and Japan. Its portfolio spans treatments for diabetes, cancer, immunological conditions, neurological disorders, and obesity, supported by strategic collaborations with companies like Boehringer Ingelheim and F. Hoffmann-La Roche.
Shares of the pharmaceutical giant have outpaced the broader market over the past 52 weeks. LLY stock has increased 43.9% over this time frame, while the broader S&P 500 Index ($SPX) has risen 8.2%. In addition, the stock has returned 25.5% on a YTD basis, compared to SPX's 7.4% gain.
More News from Barchart
Looking closer, shares of the Indianapolis, Indiana-based company has outpaced the State Street Health Care Select Sector SPDR ETF's (XLV) 24.9% increase over the past 52 weeks.
Eli Lilly shares climbed 6.6% on Oct. 29 after the company raised its 2026 revenue forecast by $5 billion to $91 billion - $92 billion and reported better-than-exected Q3 2026 revenue of $24.4 billion and adjusted EPS of $7.48. Strong demand for its injectable weight-loss and diabetes drugs drove the results, with Mounjaro sales reaching $10.72 billion versus the $10.16 billion estimate and Zepbound sales totaling $5.35 billion versus $5.09 billion, while international Mounjaro sales surged 93% to $5.7 billion.
The Medicare pilot had also brought in more than 500,000 patients for Lilly's obesity medicines, reinforcing growth prospects despite Foundayo pill sales missing estimates at $184 million and a slight reduction in the 2026 adjusted EPS outlook to $35 - $36.
For the fiscal year ending in December 2026, analysts expect LLY's adjusted EPS to jump 47.5% year-over-year to $35.70. The company's earnings surprise history is promising. It beat the consensus estimates in each of the last four quarters.
Among the 29 analysts covering the stock, the consensus rating is a "Strong Buy." That's based on 23 "Strong Buy" ratings, three "Moderate Buys," and three "Holds."
This configuration is slightly more bullish than three months ago, with 22 "Strong Buy" ratings on the stock.
On Nov. 3, Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly and set a price target of $1,508.
The mean price target of $1,490.32 represents a 9.2% premium to LLY's current price levels. The Street-high price target of $1,650 suggests a 20.9% potential upside.
On the date of publication, Sohini Mondal did not directly have a position in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
